Contract Development & Manufacturing Organisations (CDMOs) increasingly need to differentiate and establish their competitive advantage to effectively cater to the growing demand and to enhance their profitability. There is a greater demand for CDMOs offering...

Whilst the Biosimilars market represents a massive commercial opportunity, the landscape is quite complex, with multiple dynamics at play. Competition is high, and research proves that there is a strong correlation between market entry order and market uptake. How do...

To remain competitive and to take advantage of the latest innovations, life science companies can’t afford to ignore opportunities in South Korea. PharmaVentures has successfully completed over 30 projects for South Korean biotechs and pharma companies over the last 5...

More important than ever, but there’s still a way to go. Just the other week, it was announced that Illumina had acquired GRAIL (subject to approval from the regulators), a company it formed in 2016 and spun out. Illumina retained a 12% stake in the business and has...

Getting your opportunity noticed by a large pharmaceutical company is difficult, as they are continually bombarded by partnering opportunities daily. PharmaVentures has developed a unique expertise in getting their clients’ opportunities through the complex processes...

NSCLC is one of the most active areas of innovation in Oncology, and recent consensus estimates indicate that an additional $20BN of sales could be added in the indication over the next few years.

In the Spring of 2020, during the early days of the COVID-19 pandemic when there were real fears of a global downturn, PharmaVentures predicted that despite the forthcoming challenges, licensing and partnering would remain steady during 2020. With the year behind us,...

The last few years have seen a rise in nationalism and populism across the world. In 2016, the US voted in the populist Donald Trump on his promise to ‘Make America Great Again’. In 2018, Hungary re-elected its national conservative prime minister Viktor Orbán with...

Even though medical diagnosis can be traced back to ancient Egypt in the 26th century BC (Edwin Smith Papyrus by Imhotep), in vitro diagnostics (IVD) as a field really started to take shape from late 20th century. Significant investments and research have been...

At PharmaVentures, a data room is used as a location to store essential documents that are needed during an M&A or Divestment transaction. It is an essential part of the due diligence process which interested buyers access prior to closing a transaction. We...

Haematological malignancies are types of cancers affecting blood, bone marrow and lymph nodes. Broadly speaking, there are three major types of blood cancers: leukaemia, lymphoma and myeloma. Of these, the most common blood cancer types include non-Hodgkin lymphoma...

As you are aware PharmaVentures is a sector focused advisory firm and we are at the forefront of deal-making activity in the pharmaceutical, biotech, medtech and service sector industries such as CROs and CDMOs. Given the current backdrop and challenges facing...

There is strong appetite for cross-border transactions between China and the rest of the world. Improved overall market environment will encourage attractive deal terms and future market potential. Selecting the right partner and effective communication are...

This is the first in a series of white papers by the experts at PharmaVentures that explores the challenges of valuing drug candidates at various stages of clinical development. This series is based on the experiences we have encountered using valuation in actual...

In the recent years, the level of interest in Gene Therapy from both industry and academia has been unparalleled. CNS disorders in particular have gained a lot of attention with a considerable emphasis on neurological targets; and this is especially visible when...

Barely a month passes without an announcement of improved survival rates for non-small cell lung cancer (NSCLC) patients. Much of this has been driven by favouring a personalised medicine approach over the historic “one size fits all” chemotherapy paradigm. Drugs...

Despite the impressive growth observed in China over the last two decades and with a projected healthcare market of RMB 8 trillion (USD 1.2 trillion), Chinese life science companies lag behind toptiered Western counterparts, both in terms of market capitalisation and...

On May 26th 2017, a new set of European Medical Device Regulations (“MDR”) and In Vitro Diagnostic Regulations (“IVDR”) entered into force. They represent a major overhaul and tightening of the previous directives and affect all companies marketing or developing...

Today the top ten best-selling antibody therapeutics for cancer have accumulated revenues approaching $200 Billion, the bulk of which is accounted for by sales of the four leading agents.

The term Nanotechnology refers to the domain of science and engineering that is applied to structures and materials that measure only a few billionths of a meter.  The term was coined by Japanese scientist Norio Taniguchi almost 40 years ago, and then popularised...

Pain management continues to face the dual hurdles of abuse of the most efficacious (opiod based) therapies and the difficulties of developing and commercialising new treatments. This challenging environment presents difficulties both for large pharmaceutical...

It’s easy to find trading and M&A multiples for mid and top tier CROs as their financial data are plentiful, often in the public domain and are the subject of discussion both in print and at conferences globally.  Although consolidation in this sector is often...

This presentation (available download on the left-hand side of this page) provides an overview of the EM opportunity, including some analysis of the financial performance of selected EM pharmaceutical industries and respective benchmark valuation metrics....

Policy-driven changes in healthcare spending and the growing significance of generic competition are acting in tandem to force pharmaceutical manufacturing companies to adopt more cost-effective manufacturing strategies resulting in an upsurge in the level of M&A...

In deal-making, options have long been considered a useful vehicle to carry uncertainty through to a point of resolution, or at least to a position of more understandable risk. Many very early stage players prefer the use of options to allow partners an opportunity to...

The incidence of co-promotion components in biotechnology/pharmaceutical licensing deals for development products has grown steadily since 1996 according to data from PharmaDeals© V4. In 1996 just 6% of licensing deals retained co-promotion rights or options for...

The growing threat of bacterial resistance is a high priority global issue with 193 countries signing a landmark UN General Assembly declaration calling for coordinated effort in this area. Without urgent action today's routine infections could become killers and the...

The 25% rule of thumb is often quoted in the context of licensing deals royalty rates and in particular when deriving an appropriate rate of income due to a licensor for an innovative intellectual property asset. We have set out to conduct an in-depth...

With the growing understanding of numerous biologoical processes that are influenced by the 100 trillion microorganisms that make up the microbiome of an individual, there is an increasing number of Biotech and Pharma companies seeking to capitalize on this research...

Infection control is a crucial part of healthcare service delivery. Patients undergoing surgery need to be protected from infection during and after procedures. Surgical instruments are required to be cleaned and sterilised for re-use. The hospital environment needs...